Breaking News

BREAKING: Drugmaker Xspire Owes 340B Refunds

Greetings

Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.

BREAKING: Drugmaker Xspire Owes 340B Refunds

Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for overcharges to 340B covered entities for covered outpatient drugs sold from Nov. 1, 2012 to Aug. 1, 2019, according to a public notice the company posted either late late Jan. 6 or early Jan. 7 on the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) website.

Greetings Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news. BREAKING: Drugmaker Xspire Owes 340B Refunds Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds for...

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report